MedTrace Logo

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

NCT04449484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-06-03

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study of multiple ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.

Conditions

Interventions

DRUG

MEDI1341

Intravenous infusion over 60 minutes

OTHER

Placebo

Intravenous infusion over 60 minutes

Sponsors & Collaborators

Principal Investigators

  • Beth E. Safirstein, MD · MD Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2022-01-05
Completion
2022-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449484 on ClinicalTrials.gov